Effect of carnitine to hyperammonemia of liver cirrhosis.

Effect of carnitine to hyperammonemia of liver cirrhosis. - carnitine test

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022552

Enrollment

140

Registered

2016-05-31

Start date

2016-05-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis

Interventions

carnitine1000mg/day 12weeks administration and compare between two groups not treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.not administration of carnitine within 2weeks before entry 2.more than 60ug/dL of serum ammonia

Exclusion criteria

Exclusion criteria: 1.GI tract bleeding 2.giant shant vessels 3.malignat tumors which are out of control 4.patients who needs HD 5.pregnancy 6.patients who are considered as not suitable to this study

Design outcomes

Primary

Measure	Time frame
Depresion of serum ammonia after administraiton of carnitine (12W after)	—

Secondary

Measure	Time frame
Decrease evidence of hepatic encephaloapty improvement of nuber conection test B	—

Countries

Japan

Contacts

Public ContactShunsuke Nojiri

Nagoya City University Graduate School of Medical Sciences Department of Gastroenterology and Metabolism

snojiri@med.nagoya-cu.ac.jp052-853-8211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026